AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

Net Revenues

Net Revenues %Chg

Net Revenues Common Size

Cost of Products Sold

Cost of Products Sold %Chg

Cost of Products Sold Common Size

Selling, General and Administrative

Selling, General and Administrative %Chg

Selling, General and Administrative Common Size

Research and Development

Research and Development %Chg

Research and Development Common Size

Acquired IPR&D and Milestones

Acquired IPR&D and Milestones %Chg

Acquired IPR&D and Milestones Common Size

Other Operating Expense, Net

Other Operating Expense, Net %Chg

Other Operating Expense, Net Common Size

Other Operating Income

Other Operating Income %Chg

Other Operating Income Common Size

Total Operating Costs and Expenses

Total Operating Costs and Expenses %Chg

Total Operating Costs and Expenses Common Size

Operating Earnings

Operating Earnings %Chg

Operating Earnings Common Size

Interest Expense, Net

Interest Expense, Net %Chg

Interest Expense, Net Common Size

Net Foreign Exchange Loss

Net Foreign Exchange Loss %Chg

Net Foreign Exchange Loss Common Size

Other Expense, Net

Other Expense, Net %Chg

Other Expense, Net Common Size

Earnings Before Income Tax Expense

Earnings Before Income Tax Expense %Chg

Earnings Before Income Tax Expense Common Size

Income Tax Expense

Income Tax Expense %Chg

Income Tax Expense Common Size

Net Earnings

Net Earnings %Chg

Net Earnings Common Size

Net Earnings Attributable to Noncontrolling Interest

Net Earnings Attributable to Noncontrolling Interest %Chg

Net Earnings Attributable to Noncontrolling Interest Common Size

Net Earnings Attributable to AbbVie Inc.

Net Earnings Attributable to AbbVie Inc. %Chg

Net Earnings Attributable to AbbVie Inc. Common Size

Basic Earnings per Share Attributable to AbbVie Inc.

Basic Earnings per Share Attributable to AbbVie Inc. %Chg

Basic Earnings per Share Attributable to AbbVie Inc. Common Size

Diluted Earnings per Share Attributable to AbbVie Inc.

Diluted Earnings per Share Attributable to AbbVie Inc. %Chg

Diluted Earnings per Share Attributable to AbbVie Inc. Common Size

Cash Dividends Declared per Common Share

Cash Dividends Declared per Common Share %Chg

Cash Dividends Declared per Common Share Common Size

Weighted-Average Basic Shares Outstanding

Weighted-Average Basic Shares Outstanding %Chg

Weighted-Average Basic Shares Outstanding Common Size

Weighted-Average Diluted Shares Outstanding

Weighted-Average Diluted Shares Outstanding %Chg

Weighted-Average Diluted Shares Outstanding Common Size

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

Cost of Sales

Cost of Sales %Chg

Cost of Sales Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Research & Development Expenses

Research & Development Expenses %Chg

Research & Development Expenses Common Size

Other Operating Expenses

Other Operating Expenses %Chg

Other Operating Expenses Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Interest Expense

Interest Expense %Chg

Interest Expense Common Size

Non-Operating Income

Non-Operating Income %Chg

Non-Operating Income Common Size

Total Non-Operating Income

Total Non-Operating Income %Chg

Total Non-Operating Income Common Size

Income Before Provision for Income Taxes

Income Before Provision for Income Taxes %Chg

Income Before Provision for Income Taxes Common Size

Provision for Income Taxes

Provision for Income Taxes %Chg

Provision for Income Taxes Common Size

Consolidated Net Income

Consolidated Net Income %Chg

Consolidated Net Income Common Size

Net Income Attributable to Minority Interests and Other

Net Income Attributable to Minority Interests and Other %Chg

Net Income Attributable to Minority Interests and Other Common Size

Net Income Attributable to Common Shareholders

Net Income Attributable to Common Shareholders %Chg

Net Income Attributable to Common Shareholders Common Size

Basic EPS

Basic EPS %Chg

Basic EPS Common Size

Diluted EPS

Diluted EPS %Chg

Diluted EPS Common Size

Basic Weighted Average Shares Outstanding

Basic Weighted Average Shares Outstanding %Chg

Basic Weighted Average Shares Outstanding Common Size

Total Shares Outstanding

Total Shares Outstanding %Chg

Total Shares Outstanding Common Size

Diluted Weighted Average Shares Outstanding

Diluted Weighted Average Shares Outstanding %Chg

Diluted Weighted Average Shares Outstanding Common Size

EBITDA

Revenue

EBIT

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Total Revenues	28,766	29,562	26,772	28,228	26,090	29,933
Total Revenues %Chg	7.4%	4.7%	2.6%	-5.7%	-7.2%	2.4%
Net Revenues
Cost of Sales	8,348	8,608	8,296	12,189	8,226	9,192
Gross Profit	20,418	20,954	18,476	16,039	17,864	20,741
Gross Profit Margin	71%	70.9%	69%	56.8%	68.5%	69.3%
Selling, General & Administrative Expenses	6,546	8,060	6,692	6,565	6,307	6,721
Research & Development Expenses	4,198	8,904	3,887	3,650	4,025	3,404
Research and Development
Other Operating Expenses	1,047	1,649	1,101	348	251	511
Acquired IPR&D and Milestones
Other Operating Expense, Net
Other Operating Income
Operating Profit	8,627	2,341	6,796	5,476	7,281	10,105
Operating Earnings
Operating Margin	30%	7.9%	25.4%	19.4%	27.9%	33.8%
Interest Expense	-1,305	-1,201	-959	-776	-908	-973
Non-Operating Income	-4,107	-1,325	-1,936	-1,535	-3,288	-1,767
Net Foreign Exchange Loss
Other Expense, Net
Total Non-Operating Income	-5,412	-2,526	-2,895	-2,311	-4,196	-2,740
Income Before Provision for Income Taxes	3,215	-185	3,901	3,165	3,085	7,365
Earnings Before Income Tax Expense
Provision for Income Taxes	985	-1,726	1,156	560	817	941
Consolidated Net Income	2,230	1,541	2,745	2,605	2,268	6,424
Net Earnings
Net Income Attributable to Minority Interests and Other	6	2	6	5	5	2
Net Earnings Attributable to Noncontrolling Interest
Net Income Attributable to Common Shareholders	2,224	1,539	2,739	2,600	2,263	6,422
Basic EPS	1.3	0.9	1.5	1.5	1.3	3.6
Diluted EPS	1.2	0.9	1.5	1.5	1.3	3.6
Basic Weighted Average Shares Outstanding	1,768	1,769	1,769	1,768	1,768	1,772
Total Shares Outstanding	1,766	1,765.3	1,765.9	1,765.9	1,764.8	1,769.2
Diluted Weighted Average Shares Outstanding	1,772	1,774	1,772	1,773	1,773	1,779
EBITDA	12,716	6,522	11,001	9,787	11,668	14,467
Effective Tax Rate	30.6%	933%	29.6%	17.7%	26.5%	12.8%